144 related articles for article (PubMed ID: 20440538)
1. Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model.
Sandberg DI; Solano J; Petito CK; Mian A; Mou C; Koru-Sengul T; Gonzalez-Brito M; Padgett KR; Luqman A; Buitrago JC; Alam F; Wilkerson JR; Crandall KM; Kuluz JW
J Neurooncol; 2010 Dec; 100(3):397-406. PubMed ID: 20440538
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model.
Sandberg DI; Crandall KM; Koru-Sengul T; Padgett KR; Landrum J; Babino D; Petito CK; Solano J; Gonzalez-Brito M; Kuluz JW
J Neurooncol; 2010 Mar; 97(1):25-32. PubMed ID: 19688296
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy administration directly into the fourth ventricle in a nonhuman primate model.
Sandberg DI; Peet MM; Johnson MD; Cole P; Koru-Sengul T; Luqman AW
J Neurosurg Pediatr; 2012 May; 9(5):530-41. PubMed ID: 22546032
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy administration directly into the fourth ventricle in a new piglet model. Laboratory Investigation.
Sandberg DI; Crandall KM; Petito CK; Padgett KR; Landrum J; Babino D; He D; Solano J; Gonzalez-Brito M; Kuluz JW
J Neurosurg Pediatr; 2008 May; 1(5):373-80. PubMed ID: 18447671
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial.
Sandberg DI; Rytting M; Zaky W; Kerr M; Ketonen L; Kundu U; Moore BD; Yang G; Hou P; Sitton C; Cooper LJ; Gopalakrishnan V; Lee DA; Thall PF; Khatua S
J Neurooncol; 2015 Oct; 125(1):133-41. PubMed ID: 26255071
[TBL] [Abstract][Full Text] [Related]
6. High-dose MTX110 (soluble panobinostat) safely administered into the fourth ventricle in a nonhuman primate model.
Sandberg DI; Kharas N; Yu B; Janssen CF; Trimble A; Ballester LY; Patel R; Mohammad AS; Elmquist WF; Sirianni RW
J Neurosurg Pediatr; 2020 May; 26(2):127-135. PubMed ID: 32357333
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid.
Morikawa N; Mori T; Abe T; Ghoda M; Takeyama M; Hori S
Ann Pharmacother; 1997 Oct; 31(10):1153-6. PubMed ID: 9337440
[TBL] [Abstract][Full Text] [Related]
8. Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates.
Salzer W; Widemann B; McCully C; Adamson PC; Balis FM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):235-40. PubMed ID: 11592346
[TBL] [Abstract][Full Text] [Related]
9. PBPK model of methotrexate in cerebrospinal fluid ventricles using a combined microdialysis and MRI acquisition.
Brandhonneur N; Noury F; Bruyère A; Saint-Jalmes H; Le Corre P
Eur J Pharm Biopharm; 2016 Jul; 104():117-30. PubMed ID: 27142258
[TBL] [Abstract][Full Text] [Related]
10. Phase-contrast cerebrospinal fluid flow magnetic resonance imaging in qualitative evaluation of patency of CSF flow pathways prior to infusion of chemotherapeutic and other agents into the fourth ventricle.
Patel RP; Sitton CW; Ketonen LM; Hou P; Johnson JM; Romo S; Fletcher S; Shah MN; Kerr M; Zaky W; Rytting ME; Khatua S; Sandberg DI
Childs Nerv Syst; 2018 Mar; 34(3):481-486. PubMed ID: 29170836
[TBL] [Abstract][Full Text] [Related]
11. Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial.
Sandberg DI; Yu B; Patel R; Hagan J; Miesner E; Sabin J; Smith S; Fletcher S; Shah MN; Sirianni RW; Taylor MD
J Neurooncol; 2019 Jan; 141(2):449-457. PubMed ID: 30460634
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate concentration in cerebrospinal fluid of the space created by tumor removal.
Morikawa N; Mori T; Kawashima H; Takeyama M; Hori S
Biol Pharm Bull; 2000 Jun; 23(6):774-7. PubMed ID: 10864035
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of nimustine, cytosine arabinoside, and methotrexate in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.
Morikawa N; Mori T; Kawashima H; Takeyama M; Abe T; Kobayashi H
Biol Pharm Bull; 2001 Apr; 24(4):436-8. PubMed ID: 11305611
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration.
Balis FM; Blaney SM; McCully CL; Bacher JD; Murphy RF; Poplack DG
Cancer Chemother Pharmacol; 2000; 45(3):259-64. PubMed ID: 10663645
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
16. Ventricular access device placement in the fourth ventricle to treat malignant fourth ventricle brain tumors: technical note.
Sandberg DI; Kerr ML
Childs Nerv Syst; 2016 Apr; 32(4):703-7. PubMed ID: 26597683
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
[TBL] [Abstract][Full Text] [Related]
18. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats.
Wang F; Jiang X; Lu W
Int J Pharm; 2003 Sep; 263(1-2):1-7. PubMed ID: 12954175
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate in acute lymphocytic leukemia.
Freeman AI; Wang JJ; Sinks LF
Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
[TBL] [Abstract][Full Text] [Related]
20. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
